USD 28.50 billion
Report ID: SQMIG35H2165 | Region: Global | Published Date: July, 2023 | Pages: 157 | Tables: 119 | Figures: 77
Global Plasma Fractionation Market size was valued at around 28.50 billion in 2021 and is expected to rise from USD 30.87 billion in 2022 to reach a value of USD 58.24 billion by 2030, at a CAGR of 8.3 % over the forecast period (2023-2030).
Convalescent plasma was in greater demand during COVID-19 because doctors used it to treat the virus-infected patients at first. For instance, convalescent plasma was used extensively internationally to treat patients hospitalized with coronavirus and stop the progression of the disease, according to a Frontiers paper from June 2021. Convalescent plasma transfusion has been linked to better symptomatology and virus clearance, according to studies. As a result, plasma fractions were originally needed in increasing amounts to treat the COVID-19 patient. The analyzed market is anticipated to have steady expansion throughout the course of the study's prediction period as the epidemic has faded and fewer people are becoming infected with the virus.
The increasing use of immunoglobulins in various therapeutic fields, the expanding elderly population along with the rising prevalence of uncommon diseases, and the rising number of plasma collection facilities globally are some of the specific factors driving the market expansion. For instance, the percentage of people in the world over 60 will nearly treble by 2050, according to WHO statistics from October 2022. The old population of the globe is expected to age far more quickly than in the past by 2050, with 80% of them living in low- and middle-income nations. As a result, the burden of uncommon diseases is predicted to rise globally along with the aging population, raising the demand for plasma fractionation products and propelling the development of the market under investigation.
Furthermore, 1% of the world's population is thought to be affected with Von Willebrand's disease, according to an article updated by NCBI in August 2022. However, the prevalence of clinically important diseases is still thought to be around 125 per million, with severe diseases affecting up to 5 per million. Therefore, it is projected that the growing elderly population together with the burden of uncommon diseases like Von Willebrand will drive demand for plasma fractionation products, thereby promoting market growth. Additionally, the expansion of plasma collecting facilities across the globe is a key element in the development of the market under investigation. For instance, Bio Products Laboratory Ltd (BPL), a top producer of medicines using plasma-derived proteins, inaugurated its 29th plasma donation facility in April 2022. Additionally, Freedom Plasma established its fourth plasma donation facility in Ohio, US, in October 2022. Thus, expanding the number of plasma centers globally is anticipated to boost the manufacturing of plasma-based goods and consequently, market growth.
The market is also expected to grow as a result of numerous initiatives taken by the major market players, including product launches, alliances, mergers, and acquisitions, to introduce cutting-edge plasma fractionation methods and products to the marketplace. For instance, Octapharma was given permission to increase the use of cutaquig in the European Union (EU) in January 2022. Human immunoglobulin called Cutaquig is administered subcutaneously. It offers numerous patients with inherited immune deficiency flexible therapeutic options. The rising geriatric population coupled with an increase in the prevalence of rare diseases, the rising number of plasma collection centers, and various initiatives by the major market players are all predicted to have a positive impact on the market during the forecast period. The industry under study is constrained, though, by stringent laws governing the processing of plasma protein products, high prices, and problems with reimbursement.
Global Market Size
USD 28.50 billion
Largest Segment
Immunoglobulins
Fastest Growth
Immunoglobulins
Growth Rate
8.3% CAGR
To get more reports on the above market click here to Buy The Report
The global plasma fractionation market is segmented based on product, method, application, end use, and region. Based on product, the market is segmented into albumin, immunoglobulins, coagulation factors, protease inhibitors. In terms of method, the market is segmented into centrifugation, depth filtration, and chromatography. With respect to segmentation by application, the market is segmented into neurology, hematology, oncology, immunology, and pulmonology. On the basis of categorization by end use, the market is segmented into hospitals & clinics, clinical research, and others. Regionwise, the global plasma fractionation market is widespread into North America, Europe, Asia-Pacific, South America, and MEA.
Global Plasma Fractionation Market Analysis by Product
Immunoglobulin segment earned the dominant share as it is being used for the treatment, diagnosis, and administration of metabolic disorders, which is one of the major causes fueling the segment’s expansion. Immunoglobulin will therefore gain from extensive use, increasing its market share and potential.
The market for plasma fractionation is also growing due to reasons such as the approval of new drugs, the prevalence of bleeding disorders, and growing programmes & donating for patients with severe bleeding disorders like hemophilia. For instance, Grifols International SA, a provider of plasma-derived pharmaceuticals, provided blood clotting factor medications (100 million international units) for the treatment of hemophilia patients in April 2019 as part of a long-term programme to support persons with hemophilia.
Global Plasma Fractionation Market Analysis by Application
The neurology category dominated the global market in 2022 with USD 8,356.9 revenue. The global rise in neurological disease incidence is one of the primary drivers of market expansion. For instance, the Centers for Disease Control and Prevention estimates that 795,000 Americans experience a stroke each year. Additionally, the aging population poses a threat to the prevalence of neurovascular illnesses like stroke. Beyond the age of 55, the risk of having a stroke doubles, which encourages the use of plasma-based products for therapy and boosts market expansion.
On the other hand, during the anticipated time, the oncology area displays the fastest rate. With the potential for metastasis and drug resistance, demanding targets that were previously untreatable are now being addressed by an increasing array of plasma treatments for cancer. Additionally, a thorough examination of the complex effects of cold atmospheric plasma in cancer treatment is necessary to go towards the drug's widespread clinical adoption, which supports the segment's expansion.
To get detailed analysis on other segments, Request For Sample Report
North America has a 53.93% share of the regional market, dominating it. This is a result of both an increase in the prevalence of respiratory illnesses and growing knowledge of the many benefits of plasma among North American citizens. The expansion of the regional market is further aided by the existence of key players, an increase in the quantity of plasma collection facilities, a rise in the consumption of plasma collections and distribution of immunoglobulin, and the availability of plasma.
Asia Pacific is expanding as a result of tighter government regulations, favorable public and private funding for R&D, increased antibody usage, rising incidence of targeted illnesses among older people in blood-related diseases, and rising acceptance of plasma-based treatments.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Global Plasma Fractionation Market Drivers
Growing Aging Population
Respiratory illnesses and AATD are becoming more prevalent
Global Plasma Fractionation Market Restraints
High Cost of Plasma Fractionation Products
Recombinant substitutes' impact on the market
Companies in this market segment should benefit financially from recent approvals for recombinant factors such AFSTYLA (CSL), VONVENDI (Takeda/Shire), and Kovaltry (Bayer). Standard half-life products and extended half-life products are the two groups of recombinant factor products that are currently offered. The first group of recombinant factors remain in the body for the same amount of time as factor VIII or factor IX found in nature. Extended half-life products, on the other hand, have been changed to last longer in the body than conventional half-life products. Recombinant factors VIII and IX have become more popular in industrialized nations as alternatives to plasma-derived factors VIII and IX in the treatment of bleeding disorders, according to the results of the World Federation of Hemophilia's (WFH) 2020 Annual Global Survey. Recombinant factors, on the other hand, are now being used more frequently in nations like Brazil, India, and Russia. This tendency is anticipated to place certain restrictions on the development of plasma-derived coagulation factors, which will have an impact on the market's overall growth.
Speak to one of our ABIRAW analyst for your custom requirements before the purchase of this report
To improve their market position, key companies in this market are using a variety of strategies, such as alliances through mergers and acquisitions, geographic expansion, and strategic collaborations. For instance, Terumo Blood and Cell Technologies debuted its most recent production plant in May 2022 in Douglas County, Colorado. The modern production plant, which cost USD $250 million, is in line with the company's goals of improving society via healthcare and serving more people. The 170,000 square foot facility will provide one-time use collection sets for the recently FDA authorized Rika Plasma Donation System, which will give clients (Rika) access to source plasma collections.
Top Player’s Company Profiles in Global Plasma Fractionation Market
Global Plasma Fractionation Market Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates and Analyzes the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.
According to our plasma fractionation market analysis, a major factor in the market's growth is the growing proportion of elderly people in the globe, who are more susceptible to rare conditions that require the use of blood derivatives. The rising use of immunoglobulins and alpha-1-antitrypsin in numerous medical specialties around the world is also projected to fuel market expansion. The increase in blood collection facilities globally is a significant factor promoting the growth of this market.
Report Metric | Details |
---|---|
Market size value in 2021 | USD 28.50 billion |
Market size value in 2030 | USD 58.24 billion |
Growth Rate | 8.3% |
Base year | 2021 |
Forecast period | 2023-2030 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Global Plasma Fractionation Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Plasma Fractionation Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Plasma Fractionation Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Global Plasma Fractionation Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Our industry expert will work with you to provide you with customized data in a short amount of time.
SPEAK TO AN ANALYSTGet lifetime access to our reports
Basic Plan $5,000 Team Plan $10,000 SUBSCRIBE NOWPlasma Fractionation Market size was valued at USD 28.50 billion in 2021 and is poised to grow from USD 30.87 billion in 2022 to USD 58.24 billion by 2030, at a CAGR of 8.3% during the forecast period (2023-2030).
To improve their market position, key companies in this market are using a variety of strategies, such as alliances through mergers and acquisitions, geographic expansion, and strategic collaborations. For instance, Terumo Blood and Cell Technologies debuted its most recent production plant in May 2022 in Douglas County, Colorado. The modern production plant, which cost USD $250 million, is in line with the company's goals of improving society via healthcare and serving more people. The 170,000 square foot facility will provide one-time use collection sets for the recently FDA authorized Rika Plasma Donation System, which will give clients (Rika) access to source plasma collections. 'CSL Behring', 'Grifols', 'Octapharma', 'Baxalta/Shire', 'Kedrion', 'China Biologic Products Holdings', 'Sanquin', 'Bio Products Laboratory', 'Japan Blood Products Organization', 'LFB Group', 'Shanghai RAAS Blood Products', 'Green Cross Corporation', 'Baxter International Inc.', 'Takeda Pharmaceutical Company Limited', 'Beijing Tiantan Biological Products', 'Biotest AG', 'China National Pharmaceutical Group Co. (Sinopharm)', 'GC Pharma', 'ADMA Biologics', 'Emergent BioSolutions'
The aging population is another major driver of the plasma fractionation market. As people age, they are more likely to develop chronic diseases and require medical treatments, including plasma-derived products.
Growing Demand for Immunoglobulins: The demand for immunoglobulins is increasing due to their use in the treatment of immune deficiencies and autoimmune diseases. As a result, there has been a significant increase in the production and use of immunoglobulins, which is driving market growth.
North America has a 53.93% share of the regional market, dominating it. This is a result of both an increase in the prevalence of respiratory illnesses and growing knowledge of the many benefits of plasma among North American citizens. The expansion of the regional market is further aided by the existence of key players, an increase in the quantity of plasma collection facilities, a rise in the consumption of plasma collections and distribution of immunoglobulin, and the availability of plasma.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Product ID: SQMIG35H2165